The NCI conducted a Phase I trial for children and young adults with relapsed/refractory CD19 positive or CD22 positive ALL to be treated with anti CD19 or anti-CD-22 CAR-T protocols, respectively. Here, CD19 is linked to acute lymphoblastic leukemia.